Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 6Carboplatin 6Pemetrexed 5Cisplatin 5pembrolizumab 4Paclitaxel 4Docetaxel 4sargramostim 3Taxes 3Bevacizumab 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2Radiotherapy, Conformal 2Platinum 2Etoposide 2Erlotinib Hydrochloride 2Cetuximab 2vandetanib 1tetrathiomolybdate 1spartalizumab 1sintilimab 1romidepsin 1ribociclib 1nazartinib 1naporafenib 1motexafin gadolinium 1motesanib diphosphate 1methoxyamine 1fludarabine phosphate 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma of Lung × Technetium Tc 99m Sestamibi × Clear all
NCT00560495 2022-10-03

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 1 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡